Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants with type 2 diabetes.
Authors
- Giuseppe Pugliese (ORCID: https://orcid.org/0000-0003-1574-0397)
- David Z.I. Cherney (ORCID: https://orcid.org/0000-0003-4164-0429)
- Gil Chernin (ORCID: https://orcid.org/0000-0001-7514-156X)
- Kenneth W. Mahaffey (ORCID: https://orcid.org/0000-0002-3791-2148)
- Johannes F.E. Mann (ORCID: https://orcid.org/0000-0002-3154-5332)
- Katherine R. Tuttle (ORCID: https://orcid.org/0000-0002-2235-0103)
- Janusz Gumprecht (ORCID: https://orcid.org/0000-0001-7091-2118)
- Richard E. Pratley (ORCID: https://orcid.org/0000-0002-2912-1389)
- Ricardo Correa‐Rotter (ORCID: https://orcid.org/0000-0003-0100-8285)
- Ida Kirstine Bull Rasmussen (ORCID: https://orcid.org/0000-0001-6849-763X)
- Ekaterina Sokareva
- Peter R Rossing (ORCID: https://orcid.org/0000-0002-1531-4294)
- David M. Charytan (ORCID: https://orcid.org/0000-0002-7695-3583)
- Vlado Perkovic
- Søren Rasmussen
- Florian M.M. Baeres
- Mustafa Arici
- Thomas Idorn (ORCID: https://orcid.org/0009-0009-4896-5868)
- George L. Bakris
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Medical University of Silesia (PL)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Toronto (CA)
- Novo Nordisk (Denmark) (DK)
- Providence College (US)
- University of Washington (US)
- Kaplan Medical Center (IL)
- Inland Northwest Health Services (US)
- UNSW Sydney (AU)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- Translational Research Institute for Metabolism and Diabetes (US)
- Stanford Medicine (US)
- Center for Clinical Research (United States) (US)
- Kidney Centre (PK)
- New York University (US)
- Hacettepe University (TR)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- European Heart Journal
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1093/eurheartj/ehae613
- Citations
- 36
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 12.88
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Bayer
- Sanofi
- Gilead Sciences
- McMaster University
- European Commission
- Bayer HealthCare
- Novo Nordisk
- Astellas Pharma
- Intas Pharmaceuticals